AstraZeneca releases extensive real-world evidence supporting SGLT-2 inhibitors

12 March 2018

London-based AstraZeneca (LSE: AZN) has released a new analysis of data from its real-world evidence based CVD-REAL study evaluating the outcomes for type-2 diabetes patients undergoing treatment with SGLT-2 inhibitors.

The study, which compares SGLT-2 inhibitors such as AstraZeneca’s own Farxiga (dapagliflozin) with other glucose-lowering medicines, looks at data from more than 400,000 patients across six countries.

Results showed that treatment with an SGLT-2 inhibitor was associated with a 49% lower risk of death, 36% lower risk of hospitalization for heart failure, 19% lower risk of heart attack and 32% lower risk of stroke.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK